Millions of people are taking compounded weight loss drugs. Now, they're about to disappear.
Compounded GLP-1s have given rise to a cottage industry offering cheaper weight loss medications to many Americans — but now ...
Altimmune to test obesity drug for alcohol use disorder and related health conditions
Altimmune said on Thursday that it plans to test its lead experimental obesity drug, pemvidutide, to potentially treat ...
The drugstore industry is struggling. Here's what could be in its future.
But as the drugstore chain (WBA) prepares to go private and its rival CVS Health Inc. (CVS) experiments with smaller stores, some analysts and researchers see a possible future with even fewer ...
Why This Long-Time Skeptic Finally Upgraded Novo Nordisk (NVO) to Buy
Novo Nordisk (NVO), the company behind popular diabetes and obesity treatments Ozempic and Wegovy, saw its stock rise on Thursday after ...
Novo Nordisk rebounds as Kepler upgrades Ozempic maker at long last
Novo Nordisk (NVO) stock rebounds after Kepler Cheuvreux upgrades to Buy following a 42% stock drop over the past year. Read ...
Clinical Pain Advisor10h
Makers of Wegovy & Zepbound Cut Prices for Those Without Insurance
Wegovy and Zepbound — are cutting prices to make the medications more affordable for people without insurance.
Access to Compounded GLP-1s Is Drying Up. Here’s What to Know About the Copycat Weight-Loss Drugs.
To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...
Trump’s Chips War Has Left Intel’s New CEO With a Near-Impossible Task. Here’s Why and 5 Other Things to Know Today.
Cooler February inflation doesn’t mean Fed will lower rates, promising obesity drug could challenge Novo Nordisk and Eli ...
Medscape14h
The End of Compounded GLP-1s: What Physicians Need to Know
FDA ends GLP-1 drug shortage. Concerns over safety, counterfeit drugs, and high cost of brand-name versions persist; ...
Europe markets close lower as shares of alcohol companies slide after Trump threatens 200% tariffs
European markets are expected to open in mixed territory Thursday, stumbling lower as President Donald Trump’s tariffs policy upends global trading relations.
GEN - Genetic Engineering and Biotechnology News1d
Roche, Zealand Launch Up-to-$5.3B Obesity Collaboration
Roche and Zealand reason petrelintide could deliver weight loss comparable to glucagon-like peptide 1 (GLP-1) receptor ...
Medical Marketing & Media1d
Dupixent tops pharma TV ad rankings for first time in 2025
Pharma brands achieved the most impressions from ABC and saw a year-over-year increase in impressions from cable channels like Fox News, CNN and MSNBC.